Advertisement
Canada markets closed
  • S&P/TSX

    21,639.10
    -59.01 (-0.27%)
     
  • S&P 500

    5,431.60
    -2.14 (-0.04%)
     
  • DOW

    38,589.16
    -57.94 (-0.15%)
     
  • CAD/USD

    0.7284
    +0.0005 (+0.06%)
     
  • CRUDE OIL

    78.49
    -0.13 (-0.17%)
     
  • Bitcoin CAD

    90,878.66
    -594.18 (-0.65%)
     
  • CMC Crypto 200

    1,397.23
    -20.64 (-1.46%)
     
  • GOLD FUTURES

    2,348.40
    +30.40 (+1.31%)
     
  • RUSSELL 2000

    2,006.16
    -32.75 (-1.61%)
     
  • 10-Yr Bond

    4.2130
    -0.0250 (-0.59%)
     
  • NASDAQ

    17,688.88
    +21.32 (+0.12%)
     
  • VOLATILITY

    12.66
    +0.72 (+6.03%)
     
  • FTSE

    8,146.86
    -16.81 (-0.21%)
     
  • NIKKEI 225

    38,814.56
    +94.09 (+0.24%)
     
  • CAD/EUR

    0.6798
    +0.0024 (+0.35%)
     

Why Janux Therapeutics Shares Rose 33.1% This Week

Why Janux Therapeutics Shares Rose 33.1% This Week

Shares of Janux Therapeutics (NASDAQ: JANX), which specializes in immunotherapies to treat cancer, rose 33.1% this week, according to data from S&P Global Intelligence. The clinical-stage biopharmaceutical company's shares have been rising since it announced on Oct. 12 that its first patient had been dosed in its Phase 1 clinical trial of JANX007 to treat metastatic castration-resistant prostate cancer. The news was a milestone for Janux as JANX007 is the company's first product candidate using its Tumor Activated T Cell Engager (TRACTr) platform to engage T cells to fight tumors.